Dual-Responsive Bionic Transformable Silica-Based Nanoparticles Promoting Macrophage M1 Polarization for Ameliorating Glioblastoma Immunosuppressive Microenvironment

Résumé fourni par la source

Immunotherapy for glioblastoma (GBM) remains a major challenge due to the immunosuppressive tumor microenvironment, in which tumor-associated macrophages (TAMs) are a key contributor. Repolarizing TAMs from the pro-tumor M2 phenotype to the antitumor M1 phenotype offers a promising therapeutic strategy. To promote M1 polarization of TAMs and achieve stimuli-responsive controlled drug release for GBM treatment, we developed a glutathione (GSH)/pH dual-responsive bionic transformable silica-based nanoparticle vSiO 2 @JS-K/TDTCD-TA-Fe 3+ @Ang-2 which named as VTKFA. Within this nanoparticle, the nitric oxide (NO) prodrug JS-K serves as the pharmacological agent to induce TAMs repolarization. For real-time monitoring of JS-K release, we designed a NO-activated probe, TDTCD. Virus-like silica nanoparticles (vSiO 2 ) were then engineered to coload JS-K and TDTCD. A ferric–tannic network (TA–Fe 3+ ) complexed with Angiopep-2 (Ang-2) was coated onto the vSiO 2 surface, masking its original morphology. This coating disassembles under the acidic tumor microenvironment, re-exposing the bionic virus-like structure to promote rapid cellular uptake and enhanced tumor penetration. Subsequently, intracellular GSH triggers vSiO 2 degradation and JS-K release, generating NO and simultaneously activating TDTCD fluorescence. The released NO acts synergistically with hydroxyl radicals (•OH) produced via the Fenton reaction during the reduction of Fe 3+ to Fe 2+ to drive TAMs reprogramming to the M1 phenotype. This multifunctional nanoparticle, enabling both stimuli-responsive drug release and effective TAMs repolarization, is expected to alleviate the immunosuppressive microenvironment and suppress GBM progression.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.